Albert Oriol

34.7k citations
323 papers · 7.3k · 3 hit papers · h-index 44

Impact in

  • Hematology top 0.05%
    • Multiple Myeloma Research and Treatments
    • Acute Myeloid Leukemia Research
  • Oncology top 0.5%
    • Peptidase Inhibition and Analysis
    • CAR-T cell therapy research

Papers in

    • Multiple Myeloma Research and Treatments 232
    • Peptidase Inhibition and Analysis 54
    • Cancer Treatment and Pharmacology 39
    • CAR-T cell therapy research 28

Albert Oriol

312 papers receiving 7.1k citations

Albert Oriol's Hit Papers

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma 2022 · 391 citations
3910+4+9Years since publication250500750

Peers

Albert Oriol
Comparison fields: 5 of 108
  • Hematology 4.7k
  • Oncology 2.7k
  • Genetics 812
  • Public Health, Environmental and Occupational Health 1.1k
  • Molecular Biology 2.8k
Replace Jordi Esteve with:
Jordi Esteve Spain
Joseph Brandwein Canada
Anjali S. Advani United States
Giuseppe Avvisati Italy
Roy B. Jones United States
Meir Wetzler United States
Chatchada Karanes United States
Gérald Marit France
Norbert Ifrah France
Patrizia Tosi Italy
Albert Oriol relative to Jordi Esteve Spain Jordi Esteve's profile →
Citations per field
00.5×1.5×1.8×
Jordi Esteve · 1×
Citations per year

Countries citing papers authored by Albert Oriol

Since Specialization
Citations

This map shows the geographic impact of Albert Oriol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albert Oriol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albert Oriol more than expected).

Fields of papers citing papers by Albert Oriol

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Albert Oriol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albert Oriol. The network helps show where Albert Oriol may publish in the future.

Co-authors

The 25 scholars most cited alongside Albert Oriol, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Albert Oriol Line = papers co-authored together Albert Oriol links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 323 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hit paper breakdown →
2012829
2
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Hit paper breakdown →
2022391
3
Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Hit paper breakdown →
2013353
4 2017284
5 2010207
6 2008187
7 2011158
8 2002139
9 2009128
10
Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial.
2005111
11 2016109
12 2019101
13 202096
14 200886
15 201283
16 201981
17 200777
18 200174
19 200773
20 200973

About Albert Oriol

Albert Oriol is a scholar working on Hematology, Oncology, Molecular Biology, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 323 papers that have together received 7.3k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (232 papers), Protein Degradation and Inhibitors (92 papers), Peptidase Inhibition and Analysis (54 papers), Cancer Treatment and Pharmacology (39 papers), Chronic Lymphocytic Leukemia Research (35 papers), CAR-T cell therapy research (28 papers), Monoclonal and Polyclonal Antibodies Research (22 papers) and Acute Lymphoblastic Leukemia research (19 papers). The work is most often cited by research in Hematology (4.7k citations), Oncology (2.7k citations), Genetics (812 citations), Public Health, Environmental and Occupational Health (1.1k citations) and Molecular Biology (2.8k citations). Albert Oriol has collaborated with scholars based in Spain, United States and France. Frequent co-authors include Josep‐María Ribera, María‐Victoria Mateos, Jesús F. San Miguel, Evarist Feliú, Joan Bladé, Juan José Lahuerta, Laura Rosiñol, Philippe Moreau, Javier de la Rubia and Felipe de Arriba. Their work appears in journals such as Blood, Journal of Clinical Oncology, Haematologica, HemaSphere and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact